AstraZeneca: lupus drug candidate shows promise in Phase III trial
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
Archives for November 16, 2021
Gene-edited cell replacement therapy for diabetes set to enter the clinic
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D).
Pfizer inks COVID-19 treatment licensing agreement with MPP
The pact between the drug firm and the group is aimed at giving equitable access to treatments and vaccines for people in disadvantaged parts of the world.